Senators Join Biosimilar Coding Debate, Ask CMS To Withhold Draft Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
A bipartisan group of 20 US senators wrote to the Centers for Medicare and Medicaid Services asking that it not issue rules on how Medicare will reimburse biosimilars until the Food and Drug Administration has completed its regulations for the products.